{"groups":[{"description":"Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Arm 1 - VDT: VELCADE, Doxil and Low-dose Thalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT TREATED (Became ineligible)"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Other, unspecified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"Treated With Study Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"22"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}